drugset / Trial / NCT00664183

A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects

NCT00664183 ↗

Phase 2/3 Terminated 400 enrolled Vitreoretinal Technologies, Inc.
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.

Timeline

Start
2008-03
Primary completion
2009-12
Completion
—

Outcome

Outcome not reported

Stopped (Enrollment): “slow enrollment , interim analysis conducted.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitreosolve Unknown — Intravitreal

Indications